$IQST
iQSTEL Inc Stock $iqst

$iqst Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000166357724000092 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$51.41M	$47.25M	$144.5M
YoY Change	108.44%	67.88%	55.04%
Cost Of Revenue	$50.04M	$45.61M	$139.8M
YoY Change	113.37%	57.27%	52.97%
Gross Profit	$1.379M	$1.642M	$4.672M
YoY Change	13.34%	-292.36%	160.79%
Gross Profit Margin	2.68%	3.48%	3.23%
Selling, General & Admin	$1.495M	$1.345M	$4.602M
YoY Change	3.85%	7.41%	5.76%
% of Gross Profit	108.42%	81.91%	98.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$35.16K	$28.74K	$128.7K
YoY Change	3.23%	-0.55%	7.18%
% of Gross Profit	2.55%	1.75%	2.76%
Operating Expenses	$1.562M	$1.371M	$4.731M
YoY Change	1.84%	6.98%	-5.06%
Operating Profit	-$183.5K	$271.6K	-$58.96K
YoY Change	-42.23%	-112.72%	-98.15%
Interest Expense	-$365.5K	-$40.59K	$286.9K
YoY Change	-289.7%	-98.47%	-110.71%
% of Operating Profit		-14.94%
Other Income/Expense, Net	-$396.8K	-$88.29K	-$190.9K
YoY Change	-350.0%	-509.32%	-92.86%
Pretax Income	-$580.2K	$55.12K	-$219.4K
YoY Change	265.32%	-101.08%	-96.26%
Income Tax		$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$580.2K	-$124.1K	-$1.580M
YoY Change	59.76%	-97.51%	-73.53%
Net Earnings / Revenue	-1.13%	-0.26%	-1.09%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	176.3M shares	171.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.726M	$1.363M	$1.363M
YoY Change	53.36%	2.5%	2.5%
Cash & Equivalents	$2.726M	$1.363M	$1.363M
Short-Term Investments
Other Short-Term Assets	$1.500M	$759.1K	$759.1K
YoY Change	2849.27%	1494.64%	1494.64%
Inventory	$26.94K	$27.12K	$27.12K
Prepaid Expenses	$1.975M	$1.449M
Receivables	$9.000M	$12.54M	$12.54M
Other Receivables	$1.025M	$1.031M	$1.031M
Total Short-Term Assets	$15.62M	$15.72M	$15.72M
YoY Change	131.85%	144.22%	144.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$559.5K	$523.0K	$523.0K
YoY Change	29.18%	30.42%	30.42%
Goodwill	$5.172M	$5.172M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$241.0K	$641.8K	$641.8K
YoY Change	-45.85%	45.81%	45.81%
Total Long-Term Assets	$6.499M	$6.436M	$6.436M
YoY Change	5.68%	5.29%	5.29%
TOTAL ASSETS
Total Short-Term Assets	$15.62M	$15.72M	$15.72M
Total Long-Term Assets	$6.499M	$6.436M	$6.436M
Total Assets	$22.12M	$22.16M	$22.16M
YoY Change	71.64%	76.55%	76.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.615M	$2.966M	$2.966M
YoY Change	-28.88%	31.56%	31.56%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.469M	$101.9K	$101.9K
YoY Change		7.97%
Long-Term Debt Due	$103.7K	$752.6K	$752.6K
YoY Change	8.73%	697.75%	127.86%
Total Short-Term Liabilities	$13.48M	$13.84M	$13.84M
YoY Change	114.01%	114.53%	114.53%
LONG-TERM LIABILITIES
Long-Term Debt	$90.21K	$99.10K	$99.10K
YoY Change	-10.02%	-8.37%	-8.37%
Other Long-Term Liabilities	$169.7K	$169.7K	$169.7K
YoY Change	8.82%	10.05%	10.05%
Total Long-Term Liabilities	$260.0K	$268.8K	$268.8K
YoY Change	1.45%	2.46%	2.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.48M	$13.84M	$13.84M
Total Long-Term Liabilities	$260.0K	$268.8K	$268.8K
Total Liabilities	$13.74M	$13.73M	$13.73M
YoY Change	109.61%	104.53%	137.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.89M	-$26.08M
YoY Change	8.15%	6.45%
Common Stock	$177.6K	$172.1K
YoY Change	7.89%	6.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.374M	$8.424M	$8.424M
YoY Change
Total Liabilities & Shareholders Equity	$22.12M	$22.16M	$22.16M
YoY Change	71.64%	76.55%	76.55%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$580.2K	-$124.1K	-$1.580M
YoY Change	59.76%	-97.51%	-73.53%
Depreciation, Depletion And Amortization	$35.16K	$28.74K	$128.7K
YoY Change	3.23%	-0.55%	7.18%
Cash From Operating Activities	-$536.9K	-$1.054M	-$1.484M
YoY Change	-372.31%	281.59%	-15.93%
INVESTING ACTIVITIES
Capital Expenditures	$71.66K	$60.05K	$220.1K
YoY Change	13.3%	134.75%	96.34%
Acquisitions
YoY Change
Other Investing Activities	-$1.551M	$67.49K	-$112.5K
YoY Change	1846.34%	-190.35%	-94.05%
Cash From Investing Activities	-$1.623M	$7.450K	-$332.6K
YoY Change	1035.31%	-107.43%	-83.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.523M	384.0K	1.834M
YoY Change	800.96%	-4.01%	3.73%
NET CHANGE
Cash From Operating Activities	-$536.9K	-1.054M	-1.484M
Cash From Investing Activities	-$1.623M	7.450K	-332.6K
Cash From Financing Activities	$3.523M	384.0K	1.834M
Net Change In Cash	$1.363M	-662.4K	17.62K
YoY Change	204.33%	-2912.65%	-100.88%
FREE CASH FLOW
Cash From Operating Activities	-$536.9K	-$1.054M	-$1.484M
Capital Expenditures	$71.66K	$60.05K	$220.1K
Free Cash Flow	-$608.6K	-$1.114M	-$1.704M
YoY Change	-554.43%	269.14%	-9.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock		usd
CY2023	IQST	Stock Issued During Period Value Series B Preferred Issued As Dividend StockIssuedDuringPeriodValueSeriesBPreferredIssuedAsDividend		usd
CY2023	IQST	Dividend To Non Controlling Interest DividendToNonControllingInterest		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit		usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes		usd
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	IQST	Common Stock Payable Value CommonStockPayableValue		shares
CY2022	IQST	Series B Preferred Stock Issued As Dividend SeriesBPreferredStockIssuedAsDividend		usd
CY2023	IQST	Stock Issued During Period Value Asset Acquisition StockIssuedDuringPeriodValueAssetAcquisition		usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2023	IQST	Common Stock Issued For Exercise Of Cashless Warrants CommonStockIssuedForExerciseOfCashlessWarrants		usd
CY2023	IQST	Common Stock Issued For Settlement Of Debt Value2 CommonStockIssuedForSettlementOfDebtValue2		usd
CY2022	IQST	Non Cash Dividend For Collection Of Loan Receivable Related Parties NonCashDividendForCollectionOfLoanReceivableRelatedParties		usd
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-06-24
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
CY2022	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Increased By Vwap Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2022	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod
CY2023	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Increased By Vwap Outstanding Weighted Average Remaining Life ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023	IQST	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms Of Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm
CY2023	us-gaap	Dividends Dividends		usd
CY2022	us-gaap	Dividends Dividends		usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	22926663	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	176329933	shares
CY2023	dei	Auditor Firm AuditorFirmId	1013
CY2023	dei	Auditor Name AuditorName	Urish Popeck & Co., LLC
CY2023	dei	Auditor Location AuditorLocation	Pittsburgh, Pennsylvania
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1362668	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1329389	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12539774	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4209125	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	27121	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	26124	usd
CY2023Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	340515	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1449094	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	545628	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	15719172	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522997	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	99592	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5172146	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5172146	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	426755	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	440135	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	214991	usd
CY2023Q4	us-gaap	Assets Assets	22155653	usd
CY2022Q4	us-gaap	Assets Assets	12549484	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2966279	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2254636	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9993585	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2482352	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	32334	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	493164	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	94342	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	259447	usd
CY2022Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	235949	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	10428	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	101856	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1357787	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13840944	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2023Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	99099	usd
CY2022Q4	us-gaap	Loans Payable To Bank LoansPayableToBank	108150	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	169738	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	154238	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14109781	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6714067	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1200000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172129630	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172129630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161595511	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	172130	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	161595	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34360884	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31136120	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26084133	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24504395	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25340	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33557	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-377710	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-924377	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8045872	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5835417	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22155653	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12549484	usd
CY2023	us-gaap	Revenues Revenues	144502351	usd
CY2022	us-gaap	Revenues Revenues	93203532	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	139830338	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	91412016	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4987516	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4983176	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4987516	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4983176	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-315503	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3191660	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	118871	usd
CY2023	IQST	Interest Expense2 InterestExpense2	94908	usd
CY2023	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	381848	usd
CY2022	IQST	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss1 FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss1	-2650369	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	96067	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2674101	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-219436	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5865761	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-219436	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5865761	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	543822	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	101713	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-763258	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5967474	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	816480	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1579738	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5967474	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-219436	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5865761	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-16112	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-6080	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-203324	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5859681	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	551717	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	104692	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-755041	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5964373	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	167281028	shares
CY2022	IQST	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	151850443	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7416911	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1550000	usd
CY2022	IQST	Stock Issued During Period Value Asset Acquisition StockIssuedDuringPeriodValueAssetAcquisition	357500	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	107600	usd
CY2022	IQST	Common Stock Issued For Settlement Of Debt Value1 CommonStockIssuedForSettlementOfDebtValue1	80674	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2022	IQST	Common Stock Payable Value CommonStockPayableValue	18900	shares
CY2022	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	1792582	usd
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	3101	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-5967474	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6759794	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42890	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1400000	usd
CY2023	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	975939	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	8217	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-763258	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8423582	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-219436	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5865761	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	42890	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	126500	usd
CY2023	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	8815	usd
CY2022	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	34376	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	7200	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	128737	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	120117	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	38758	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	7407	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-381848	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	2650369	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	53568	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8010726	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	799533	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-997	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-26124	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1085279	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23728	usd
CY2023	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	93264	usd
CY2022	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	96863	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1217926	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-265511	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	6623327	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2179965	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1483801	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1765060	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1889132	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	220045	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	112074	usd
CY2023	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	192154	usd
CY2022	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	1000	usd
CY2023	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	79649	usd
CY2022	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	700	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-332550	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2001506	usd
CY2023	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	375000	usd
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	18559	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	232018	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1100000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1400000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
CY2023	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	250000	usd
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	500000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	172476	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1833965	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1767982	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15665	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6840	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	33279	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2005424	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3334813	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1362668	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1329389	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	45282	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3333	usd
CY2022	IQST	Common Stock Payable Value CommonStockPayableValue	18900	shares
CY2023	IQST	Series B Preferred Stock Issued As Dividend SeriesBPreferredStockIssuedAsDividend	816480	usd
CY2022	IQST	Stock Issued During Period Value Asset Acquisition StockIssuedDuringPeriodValueAssetAcquisition	357500	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1550000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	80674	usd
CY2022	IQST	Common Stock Issued For Exercise Of Cashless Warrants CommonStockIssuedForExerciseOfCashlessWarrants	3790	usd
CY2022	IQST	Common Stock Issued For Settlement Of Debt Value2 CommonStockIssuedForSettlementOfDebtValue2	80674	usd
CY2023	IQST	Non Cash Dividend For Collection Of Loan Receivable Related Parties NonCashDividendForCollectionOfLoanReceivableRelatedParties	5050	usd
CY2023	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	975939	usd
CY2022	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	1792582	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zFafJoxFJrfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The preparation of the consolidated financial statements in conformity with GAAP in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	8815	usd
CY2022	us-gaap	Allowance For Loan And Lease Loss Recovery Of Bad Debts AllowanceForLoanAndLeaseLossRecoveryOfBadDebts	34376	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	26600	usd
CY2023Q4	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2022Q4	us-gaap	Advance Payments Netted Against Claim Receivable AdvancePaymentsNettedAgainstClaimReceivable	21000	usd
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	428	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	389	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	357500	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	20000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1449094	usd
CY2023	IQST	Conideration Of Whisl ConiderationOfWhisl	<table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ConiderationOfWhisl_zKPK7R2stcd9" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; width: 50%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - NOTE 4 - ACQUISITIONS - Whisl Consideration (Details)"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 13,</b></span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Consideration:</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20220513__us-gaap--BusinessAcquisitionAxis__custom--WhislTelecomLLCMember_zK0E1m9qP1ea">1,250,000</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220513__20220513__us-gaap--BusinessAcquisitionAxis__custom--WhislTelecomLLCMember_z50ejU5lIl04">1,461,653</span> shares of common stock</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220513__20220513__us-gaap--BusinessAcquisitionAxis__custom--WhislTelecomLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--RestrictedStockMember_zV5zI7Th0Bi4">550,000</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Purchase Price</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--AcquisitionCostsCumulative_iI_c20220601__us-gaap--BusinessAcquisitionAxis__custom--SmartbizTelecomLLCMember_zrnxhN2MKyci">1,800,000</span></span></td> <td> </td></tr> </table>
CY2023	IQST	Conideration Of Smartbiz ConiderationOfSmartbiz	<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ConiderationOfSmartbiz_zQXBXaBDrAV4" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; width: 50%; border-collapse: collapse; margin-right: auto" summary="xdx: Disclosure - NOTE 4 - ACQUISITIONS - Smartbiz Consideration (Details)"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 1,</b></span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Consideration:</b></span></td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 65%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 30%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_c20220601__us-gaap--BusinessAcquisitionAxis__custom--SmartbizTelecomLLCMember_z5z7FGPkH8P">800,000</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220601__20220601__us-gaap--BusinessAcquisitionAxis__custom--SmartbizTelecomLLCMember_z7UkBGHVtGZ1">2,850,330</span> shares of common stock</span></td> <td> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20220601__20220601__us-gaap--BusinessAcquisitionAxis__custom--SmartbizTelecomLLCMember_zDwrLnBiYWu">1,000,000</span></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Purchase Price</span></td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--AcquisitionCostsCumulative_iI_c20220601__us-gaap--BusinessAcquisitionAxis__custom--SmartbizTelecomLLCMember_zgmNwW8pmVz8">1,800,000</span></span></td> <td> </td></tr> </table>
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	312116	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	120139	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	738050	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	545628	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	800435	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	656629	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	522997	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	401021	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	128737	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	120117	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	624597	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	202492	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	592263	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	202492	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	493164	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	94342	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	99099	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108150	usd
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_80B_eus-gaap--DerivativesReportingOfDerivativeActivity_z9ACWmGmJRmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 – WARRANTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 5, 2022, we entered into a Common Stock Purchase Option Agreement with Apollo Management Group, Inc (Holder) to subscribe for and purchase from the Company, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zt7jevJZvhgb">4,800,000</span> shares of Common Stock with an exercise price per share of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zysylO3T0v6j">$2.00</span>; and an initial exercisable date on <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zRNMGOfbQw64">September 30, 2022</span>. The purchase price of this option was <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zxVOUtrU7GIj">$500,000</span>. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternatives_c20220405__20220405__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zFJr24wSKKVa">The Holder and the Company agreed that the Holder had the right and the obligation to exercise, on a cashless basis, $1,000,000 of the Options not later than October 15, 2022. Thereafter, the Holder shall undertake to exercise not less than (i) <span id="xdx_90E_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20221114_zZlaNxY3lwn5">$400,000</span> of the Options on a “cash basis” not later than the later of (y) <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20221114__us-gaap--DebtInstrumentAxis__custom--ApolloOptionMember_zlS6A7a89UVb">November 14, 2022</span> or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder and (ii) an additional <span id="xdx_905_eus-gaap--OptionIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_iI_c20221214__us-gaap--DebtInstrumentAxis__custom--ApolloOptionAdditionalMember_zKNRjVstvDg2">$400,000</span> of the Options on a “cash basis” not later than the latest of (x) thirty (30) days following the exercise of the Option under subsection (i), above, (y) December 14, 2022, or (z) the date on which there is an effective registration statement permitting the issuance of the Option Shares to or resale of the Option Shares by the Holder</span>. From and after the occurrence of the three above-referenced exercises, each additional exercise of Options hereunder shall be in an amount not less than $200,000 and exercised only on a cash basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90A_eus-gaap--DebtInstrumentCallFeature_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ApolloManagementGroupMember_zAAzFgO26GC5">The Holder’s obligation to exercise each specified portion of this option on the specific dates above is subject to the volume-weighted average price (“VWAP”, market value), being not less than $0.20 per share on the relevant option exercise date. Adjusted option shares at VWAP of $0.20 shall be 48,000,000 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">A summary of activity regarding warrants issued as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zfk7FX7osFTg" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto" summary="xdx: Disclosure - NOTE 9 - WARRANTS - Schedule of Warrant Summary (Details)"> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Warrants Outstanding</b></td><td style="padding-bottom: 1pt"><b> </b></td> <td colspan="3"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td><b> </b></td> <td colspan="3"><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average</b></td><td style="font: 10pt Times New Roman, Times, Serif"><b> </b></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Weighted Average Remaining</b></td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Shares</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Exercise Price</b></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Contractual life (in years)</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Outstanding, December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20211231_zSitfIk8IyGe"><span style="-sec-ix-hidden: xdx2ixbrl0955">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20211231_zxKj70mZAkjg"><span style="-sec-ix-hidden: xdx2ixbrl0956">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_d0_c20211231_ze6fW342bcBe"><span style="-sec-ix-hidden: xdx2ixbrl0957">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; padding-left: 5.4pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zYNC8f1F0vcj">4,800,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20211231__20211231_zcA4q5L4brRd">2.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span id="xdx_906_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_dtY_c20220101__20221231_zBxnWOEktP1">1.49</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Increase in number of warrants by VWAP</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20220101__20221231_zKr2XeDHfBY8">32,467,713</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_ecustom--IncreaseInNumberOfWarrantsWeightedAverageExercisePrice_c20211231__20211231_zUVPdFd1q5ih">0.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife_d0_c20220101__20221231_zLGVa3kKX1Dl"><span style="-sec-ix-hidden: xdx2ixbrl0963">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20221231_zpe3PHdXoNK7">14,155,138</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20211231__20211231_znRUnssRYXSb">0.18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231_zWkEUZFU78Qi">0.97</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt">Forfeited/canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231_zRYW6sQlSgff"><span style="-sec-ix-hidden: xdx2ixbrl0967">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20211231__20211231_zVWhdH52FYs5"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20220101__20221231_zWh0wEZFOtsb"><span style="-sec-ix-hidden: xdx2ixbrl0969">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20221231_zjXOArtCRqHl">23,112,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20221231_z1DqbahF4FBg">0.17</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_z5QPoonQ9QRe">0.75</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_zbRgwDR4iPkf"><span style="-sec-ix-hidden: xdx2ixbrl0973">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_znTcWB4v0Tjf"><span style="-sec-ix-hidden: xdx2ixbrl0974">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_ecustom--WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod_d0_c20230101__20231231_zgfVN6xHt5we"><span style="-sec-ix-hidden: xdx2ixbrl0975">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Increase in number of warrants by VWAP</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_c20230101__20231231_zmDD07lgn5Vd">5,262,465</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_ecustom--IncreaseInNumberOfWarrantsWeightedAverageExercisePrice_c20230101__20231231_zODVU42lBZs">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIncreasedByVWAPOutstandingWeightedAverageRemainingLife_d0_c20230101__20231231_zxL7t1ws46f2"><span style="-sec-ix-hidden: xdx2ixbrl0978">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231_zfBzuZVh4MPa">10,294,119</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z9dYfhTGTXoh">0.14</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231_zx7NHlhMhKH9">0.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt">Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231_zlfKeSOXEsHi">18,080,921</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230101__20231231_z9nkCtOpHgx7"><span style="-sec-ix-hidden: xdx2ixbrl0983">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOfForfeited_d0_c20230101__20231231_zWHySaDTrBNg"><span style="-sec-ix-hidden: xdx2ixbrl0984">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding, December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231_zutxfnTy8F7a"><span style="-sec-ix-hidden: xdx2ixbrl0985">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20231231_z0lMCp7Zkq2g"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231_zDd54iW7S52a"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span></span> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	400000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4800000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.00
CY2022	IQST	Weighted Average Remaining Life Of Warrants Granted In Period WeightedAverageRemainingLifeOfWarrantsGrantedInPeriod	P1Y5M26D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	32467713	shares
CY2021Q4	IQST	Increase In Number Of Warrants Weighted Average Exercise Price IncreaseInNumberOfWarrantsWeightedAverageExercisePrice	0.17
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	14155138	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.18
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y11M19D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	23112575	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.17
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y9M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	5262465	shares
CY2023	IQST	Increase In Number Of Warrants Weighted Average Exercise Price IncreaseInNumberOfWarrantsWeightedAverageExercisePrice	0.14
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	10294119	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.14
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P0Y8M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	18080921	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0467	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0555	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0006	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0473	pure
CY2022	us-gaap	Debtor Reorganization Items Write Off Of Deferred Financing Costs And Debt Discounts DebtorReorganizationItemsWriteOffOfDeferredFinancingCostsAndDebtDiscounts	500000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	943833	usd
CY2022	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	1792582	usd
CY2022	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	1706536	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1357787	usd
CY2023	IQST	Resolution Of Derivative Liabilities Value ResolutionOfDerivativeLiabilitiesValue	975939	usd
CY2023	us-gaap	Debt Securities Held To Maturity Transfer Derivative Hedge Gain Loss DebtSecuritiesHeldToMaturityTransferDerivativeHedgeGainLoss	381848	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	943833	usd
CY2023	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities	381848	usd
CY2022	IQST	Revaluation Of Derivative Liabilities RevaluationOfDerivativeLiabilities	1706536	usd
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	381848	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	2650369	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	240000	shares
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42890	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1400000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1550000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	107600	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	400000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172129630	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172129630	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	161595511	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	161595511	shares
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13457361	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15540294	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	21	pure
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2826046	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3263462	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	7276	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	7118	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2392015	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2816209	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	426755	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	440135	usd
CY2023Q4	IQST	Deferred Tax Assets Operating Loss Carryforwards Approximate DeferredTaxAssetsOperatingLossCarryforwardsApproximate	-13500000	usd
CY2023Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	340515	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Related Parties LoansAndLeasesReceivableRelatedParties	326324	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2022Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	26613	usd
CY2023	us-gaap	Management Fee Expense ManagementFeeExpense	516000	usd
CY2022	us-gaap	Management Fee Expense ManagementFeeExpense	576000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	42890	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	107600	usd
CY2023Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	100128	usd
CY2022Q4	us-gaap	Financial Guarantee Insurance Contracts Risk Management Activities Mitigating Claim Liabilities Accrued Liabilities FinancialGuaranteeInsuranceContractsRiskManagementActivitiesMitigatingClaimLiabilitiesAccruedLiabilities	79628	usd
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	5954	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	73865	usd
CY2023	us-gaap	Revenues Revenues	144502351	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	139830338	usd
CY2023	us-gaap	Gross Profit GrossProfit	4672013	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4987516	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-315503	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	96067	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-219436	usd
CY2022	us-gaap	Revenues Revenues	93203532	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	91412016	usd
CY2022	us-gaap	Gross Profit GrossProfit	1791516	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4983176	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3191660	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2674101	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-5865761	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	15719172	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6436481	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13840944	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	268837	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6436590	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6112894	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6451679	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	262388	usd

Files In Submission

Name	View Source	Status
0001663577-24-000092-index-headers.html	Edgar Link	pending
0001663577-24-000092-index.html	Edgar Link	pending
0001663577-24-000092.txt	Edgar Link	pending
0001663577-24-000092-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
iqst-20231231.xsd	Edgar Link	pending
iqst10k_123123.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
iqst-20231231_cal.xml	Edgar Link	unprocessable
iqst-20231231_lab.xml	Edgar Link	unprocessable
iqst-20231231_pre.xml	Edgar Link	unprocessable
iqst-20231231_def.xml	Edgar Link	unprocessable
iqst10k_123123_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IQST
iQSTEL Inc Stock $iqst

2024 Q1 Form 10-K Financial Statement

#000166357724000092 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST iQSTEL Inc Stock $iqst

2024 Q1 Form 10-K Financial Statement

#000166357724000092 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IQST
iQSTEL Inc Stock $iqst